Cocrystal Pharma’s Promising Drug Developments Garner Buy Rating from Analyst
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report) today and set a price target of ...
Nasdaq1mon
Cocrystal Pharma Announces Enrollment Extension in Phase 2a Study of Influenza Treatment CC-42344 Due to Low Infection Rates
CC-42344 has demonstrated excellent in vitro ... disease and have a high barrier to viral resistance. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company ...
Finanznachrichten1mon
Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
CC-42344 is a drug candidate in development as an oral treatment for pandemic avian and seasonal influenza A infections. In December 2023, Cocrystal Pharma announced enrollment of the first ...